Evaluates the status of the woman’s endometrial receptivity to prevent implantation failure
An endometrium is receptive when it is ready for embryo implantation. This occurs around days 19-21 in each menstrual cycle of a fertile woman. This period of receptivity is what we call the window of implantation.
The lack of synchronisation between the embryo ready to be implanted and endometrial receptivity is one of the causes of recurring implantation failure. This is why it is imperative to assess the endometrium in order to determine the optimal day for embryo transfer.
The ERA test requires an endometrial biopsy that should be carried out on day hCG+7 (natural cycle) or day P+5 (HRT cycle). This biopsy is quickly and easily taken by a gynecologist in their consultation room and sent to Igenomix for testing.
The ERA test analyses the expression levels of 248 genes linked to the status of endometrial receptivity, using RNA sequencing taken from the endometrial tissue.
Following the analysis, a specific computational predictor classifies the samples according to their expression profile as Receptive or Non-Receptive.
The Endometrial Receptivity Anaysis (ERA®) has been designed, developed and patented by IGENOMIX (PCT/ES2009/000386)..
(*SREI Prize Paper 2016. 0-115 Simón et al. on behalf of the ERA RCT Consortium.)
The ERA test is performed with Next Generation Sequencing (NGS) technology
Our experts are professional, reliable and approachable and are available to help guide both professionals and patients throughout the entire process. We are proud to deliver high quality results for every test, every day.
ERA tests performed